Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Sternberg

Showing results (341-350 of 564) with videos related to

Pageof 57
Sort By:
The Prostate|July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapyJudith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.
Cancer Treatment Reviews|June 24, 2020
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakesMélanie Claps, Alessia Mennitto, Valentina Guadalupi, et al.
Clinical Genitourinary Cancer|May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityJoaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.
Oncology|October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.
British Journal of Cancer|July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinomaA J Zurita, R C Gagnon, Y Liu, et al.
The Oncologist|October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS TrialNeal D Shore, Maha Hussain, Fred Saad, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Pageof 57

Showing results (341-350 of 564) with videos related to

Sort By:
Pageof 57
The Prostate|July 10, 2023
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapyJudith Stangl-Kremser, Michael Sun, Benedict Ho, et al.
Journal for Immunotherapy of Cancer|January 10, 2023
New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitorsAristotelis Bamias, Axel Merseburger, Yohann Loriot, et al.
British Journal of Cancer|August 1, 1994
Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group StudyC N Sternberg, W W ten Bokkel Huinink, J F Smyth, et al.
Cancer Treatment Reviews|June 24, 2020
Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakesMélanie Claps, Alessia Mennitto, Valentina Guadalupi, et al.
Clinical Genitourinary Cancer|May 6, 2014
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicityJoaquim Bellmunt, Francesc Pons, Abigail Foreshew, et al.
Oncology|October 2, 2013
Larotaxel with Cisplatin in the first-line treatment of locally advanced/metastatic urothelial tract or bladder cancer: a randomized, active-controlled, phase III trial (CILAB)Cora N Sternberg, Iwona A Skoneczna, Daniel Castellano, et al.
British Journal of Cancer|July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinomaA J Zurita, R C Gagnon, Y Liu, et al.
The Oncologist|October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS TrialNeal D Shore, Maha Hussain, Fred Saad, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Pageof 57